<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nusinersen: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nusinersen: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nusinersen: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="111433" href="/d/html/111433.html" rel="external">see "Nusinersen: Drug information"</a> and <a class="drug drug_patient" data-topicid="111434" href="/d/html/111434.html" rel="external">see "Nusinersen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49321714"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Spinraza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872232"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Spinraza</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F49334558"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antisense Oligonucleotide</span></li></ul></div>
<div class="block don drugH1Div" id="F53462702"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a03d9527-e044-4e1a-ae21-fb78e0d4dd74">Spinal muscular atrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal muscular atrophy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Intrathecal: 12 mg once every 14 days for 3 doses; then 12 mg once 30 days after the third dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: Intrathecal: 12 mg once every 4 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses:</i> Loading dose (any of the 4): Administer the missed loading dose as soon as possible and adjust the date for the subsequent doses to maintain the recommended interval between doses.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F49323094"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a03d9527-e044-4e1a-ae21-fb78e0d4dd74">Spinal muscular atrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal muscular atrophy:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Intrathecal: 12 mg once every 14 days for 3 doses; then 12 mg once 30 days after the third dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: Intrathecal: 12 mg once every 4 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (any of the 4): Administer the missed loading dose as soon as possible and adjust the date for the subsequent doses to maintain the recommended interval between doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;8 months from the last dose: Administer the missed maintenance dose as soon as possible and then administer the next maintenance dose per the original scheduled date, as long as the 2 doses are administered 14 days apart.</p>
<p style="text-indent:-2em;margin-left:8em;">≥8 months and &lt;16 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by one additional dose 14 days later, and then administer the next maintenance dose 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥16 months and &lt;40 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by 2 additional doses 14 days apart, and then administer the next maintenance dose 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 months from the last dose: Restart dosing from the beginning.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51131266"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51131267"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F49323093"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="111433" href="/d/html/111433.html" rel="external">see "Nusinersen: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a03d9527-e044-4e1a-ae21-fb78e0d4dd74">Spinal muscular atrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal muscular atrophy:</b>
<b>Intrathecal:</b> Loading dose: 12 mg once every 14 days for 3 doses; then 12 mg as a single dose 30 days after the third dose, followed by maintenance dosing. Maintenance: 12 mg once every 4 months.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i></p>
<p style="text-indent:-2em;margin-left:4em;">US labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (any of the 4): Administer the missed loading dose as soon possible and adjust the date for the subsequent doses to maintain the recommended interval between doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;8 months from the last dose: Administer the missed maintenance dose as soon as possible and then administer the next maintenance dose per the original scheduled date, as long as the 2 doses are administered 14 days apart.</p>
<p style="text-indent:-2em;margin-left:8em;">≥8 months and &lt;16 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by one additional dose 14 days later, and then administer the next maintenance dose 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥16 months and &lt;40 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by 2 additional doses 14 days apart, and then administer the next maintenance dose 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 months from the last dose: Restart dosing from the beginning.</p>
<p style="text-indent:-2em;margin-left:4em;">Canadian labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Second and third dose: Administer the missed loading dose as soon possible, with at least 14 days between doses, then continue with subsequent doses at the prescribed intervals from the last dose. If the third loading dose is administered ≥8 months from the last dose, follow same recommendation as for the maintenance dose for the same duration of dose interruption. If a loading dose is delayed ≥40 months from the last dose, restart from the beginning.</p>
<p style="text-indent:-2em;margin-left:8em;">Fourth dose:</p>
<p style="text-indent:-2em;margin-left:10em;">≤5 months from the third loading dose: Administer the missed loading dose as soon as possible and then administer the first maintenance dose 4 months later and then subsequent maintenance doses every 4 months.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;5 months to &lt;8 months from the third loading dose: Administer the missed loading dose as soon as possible, then administer the first maintenance dose 8 months from the third loading dose, with at least 14 days between dose, and then subsequent maintenance doses every 4 months after the last dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥8 months to &lt;16 months from the third loading dose: Administer the missed loading dose as soon as possible, followed by 2 additional doses 14 days apart, and then subsequent maintenance doses every 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:10em;">≥16 months to &lt;40 months from the last dose: Administer the missed loading dose as soon as possible, followed by 2 additional doses 14 days apart, and then subsequent maintenance doses every 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:10em;">≥40 months from the third loading dose: Restart dosing from the beginning with a loading regimen and subsequent maintenance doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;4 months to &lt;8 months from the last dose: Administer the missed maintenance dose as soon as possible and then administer the next maintenance dose per the original scheduled date, as long as the 2 doses are administered 14 days apart and then administer the next maintenance dose every 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥8 months and &lt;16 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by 1 additional dose 14 days later, and then administer the next maintenance dose every 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥16 months and &lt;40 months from the last dose: Administer the missed maintenance dose as soon as possible, followed by 2 additional doses 14 days apart, and then administer the next maintenance dose every 4 months thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 months from the last dose: Restart dosing from the beginning with a loading regimen and subsequent maintenance doses.</p></div>
<div class="block dora drugH1Div" id="F50991862"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989161"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F49308086"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (35%), vomiting (29%), period of tooth development (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (58%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Lower respiratory tract infection (55%), atelectasis (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (43%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fall (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Seasonal allergy (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory congestion (5%; upper tract: 8%), epistaxis (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Angioedema, aseptic meningitis, hydrocephalus, hypersensitivity reaction, maculopapular rash, meningitis, serious infection, skin rash</p></div>
<div class="block coi drugH1Div" id="F49305338"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known or suspected hypersensitivity to nusinersen or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F49323082"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Coagulation abnormalities and thrombocytopenia (including acute severe thrombocytopenia) have been observed with some antisense oligonucleotides; increased risk of bleeding complications may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal toxicity, including potentially fatal glomerulonephritis, has been observed with some antisense oligonucleotides. For urinary protein concentration &gt;0.2 g/L, consider repeat testing and further evaluation.</p></div>
<div class="block foc drugH1Div" id="F49321715"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Spinraza: 12 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F49321713"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F49483347"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Spinraza Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 mg/5 mL (per mL): $33,096.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872233"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Spinraza: 12 mg/5 mL (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614656"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intrathecal use only. Allow vial to warm to room temperature before use; do not use external heat sources. Prior to administration, remove 5 mL of cerebrospinal fluid. Administer as an intrathecal bolus injection over 1 to 3 minutes using spinal anesthesia needle. Do not administer in areas with signs of infection or inflammation.</p></div>
<div class="block adm drugH1Div" id="F49323098"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For intrathecal use only. Allow vial to warm to room temperature before use; do not use external heat sources. Prior to administration, remove 5 mL of cerebrospinal fluid. Administer as an intrathecal bolus injection over 1 to 3 minutes. Do not administer in areas with signs of infection or inflammation.</p></div>
<div class="block sts drugH1Div" id="F49323085"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials between 2°C to 8°C (36°F to 46°F) in original carton,  protected from light. Do not freeze.  May store intact vials at or below 30°C (86°F) for up to 14 days in original carton, protected from light. Intact vials in original carton may be removed from and returned to the refrigerator, if necessary; if removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours at a temperature not exceeding 25°C (77°F). Following removal from vial, administer solution within 4 hours; discard unused contents of the vial.</p></div>
<div class="block usep drugH1Div" id="F53571395"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of spinal muscular atrophy (SMA) (FDA approved in all ages)</p></div>
<div class="block mst drugH1Div" id="F56412969"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F49322590"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F49322587"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F49323080"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571394"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Platelet count, coagulation tests (prothrombin time; activated partial thromboplastin time), and quantitative spot urine protein testing at baseline, prior to each dose, and as clinically indicated</p></div>
<div class="block pha drugH1Div" id="F49323086"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Treats spinal muscular atrophy caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency by binding to a specific sequence in the intron downstream of exon 7 of the <i>SMN2</i> messenger ribonucleic acid (mRNA) transcript and increasing production of full-length SMN protein.</p></div>
<div class="block phk drugH1Div" id="F49323087"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Within the CNS and peripheral tissues</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via exonuclease (3’- and 5’)-mediated hydrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal (mean range): CSF: 135 to 177 days;  Plasma: 63 to 87 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak (median range): 1.7 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50615700"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Spinraza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Spinraza (nusinersen) [prescribing information]. Cambridge, MA: Biogen; February 2023.</div>
</li>
<li>
<div class="reference">
                  Spinraza (nusinersen) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 111694 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
